Liu Jing-Jing, Wang Si-Min, Zhang Zi-Han, Wang Xue-Qian, Zhang Xiao-Hui, Wang Hong-Ying, Chen Ting
Department of Biochemistry and Molecular Biology, Suzhou Medical College of Soochow University, 199 Ren'ai Rd, Suzhou, 215123, China.
MOE Key Laboratory of Geriatric Diseases and Immunology, Soochow University, Suzhou, China.
World J Pediatr. 2025 May 27. doi: 10.1007/s12519-025-00918-2.
Mitochondrial diseases are among the most common metabolic disorders caused by mitochondrial dysfunction. Analyzing mitochondrial respiratory chain enzyme activity is essential for diagnosis. However, clinical laboratories often rely on mitochondria isolated from muscle biopsies or cultured skin fibroblasts, which may be unacceptable for some pediatric patients. This highlights the need for improved blood-based diagnostic methods.
This paper describes spectrophotometric assays to evaluate mitochondrial respiratory chain enzyme activity in peripheral blood monocytes. Sample preparation methods and assays for respiratory complexes I-IV and the mitochondrial matrix enzyme citrate synthase are detailed. The assays were validated via samples from a panel of 28 healthy children and validated in patients with combined and isolated mitochondrial oxidative phosphorylation system (OXPHOS) deficiency.
The citrate synthase-normalized activities were 0.23 ± 0.08 for complex I, 0.22 ± 0.081 for complex II, 0.16 ± 0.07 for complex III, and 0.22 ± 0.07 for complex IV. All patients with mitochondrial disease exhibited the expected reductions in respiratory complex activity.
We established a method to analyze the respiratory complex activities via blood samples. The normal enzymatic activity ranges were established from healthy Chinese pediatric populations. We also validated the assay via samples from patients with mitochondrial disease. By establishing the first pediatric-specific reference ranges for mitochondrial respiratory chain complex activities in a Chinese population and validating this minimally invasive blood-based assay in patients with mitochondrial disease, our study enabled earlier detection, precise monitoring, and personalized management of mitochondrial disorders while avoiding the need for invasive tissue biopsies.
线粒体疾病是由线粒体功能障碍引起的最常见的代谢紊乱疾病之一。分析线粒体呼吸链酶活性对诊断至关重要。然而,临床实验室通常依赖从肌肉活检或培养的皮肤成纤维细胞中分离出的线粒体,这对一些儿科患者来说可能难以接受。这凸显了改进基于血液的诊断方法的必要性。
本文描述了用于评估外周血单核细胞中线粒体呼吸链酶活性的分光光度法。详细介绍了呼吸复合体I-IV和线粒体基质酶柠檬酸合酶的样品制备方法和检测方法。通过28名健康儿童的样本对这些检测方法进行了验证,并在合并和孤立的线粒体氧化磷酸化系统(OXPHOS)缺陷患者中进行了验证。
以柠檬酸合酶标准化后的活性,复合体I为0.23±0.08,复合体II为0.22±0.081,复合体III为0.16±0.07,复合体IV为0.22±0.07。所有线粒体疾病患者的呼吸复合体活性均出现预期降低。
我们建立了一种通过血液样本分析呼吸复合体活性的方法。从健康的中国儿科人群中确定了正常酶活性范围。我们还通过线粒体疾病患者的样本对该检测方法进行了验证。通过建立中国人群中首个针对儿科的线粒体呼吸链复合体活性参考范围,并在患有线粒体疾病的患者中验证这种微创的基于血液的检测方法,我们的研究能够实现线粒体疾病的早期检测、精确监测和个性化管理,同时避免了侵入性组织活检的需要。